MiNK Therapeutics, Inc. Insider Trading
INKT
Insiders sold 120K and bought nothing on the open market.
None of the selling was scheduled in advance under a 10b5-1 plan. The last open-market buy by an executive or director was in May 2023.
Get an email when INKT's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Oct 12 | Jennifer Buell Chief Executive Officer | SoldNo plan | 6,938 | $10.56 | 73K | 8.6% | Form 4 |
| Jun 4 | Barbara Ryan Director | SoldNo plan 2 parts | 1,500 | $12.76 average | 19K | 6.4% | Form 4 |
| Mar 9 – 10 | Barbara Ryan Director | SoldNo plan 4 parts | 1,500 | $14.70 average | 22K | 6.8% | Form 4 |
| Feb 27 – Mar 2 | Barbara Ryan Director | SoldNo plan 2 parts | 500 | $10.85 average | 5K | 2.2% | Form 4 |
- Oct 12No planJennifer BuellChief Executive Officer · sold 6,938 at $10.5673K8.6% of stake
- Jun 4No planBarbara RyanDirector · sold 1,500 at avg $12.7619K6.4% of stake
- Mar 9 – 10No planBarbara RyanDirector · sold 1,500 at avg $14.7022K6.8% of stake
- Feb 27 – Mar 2No planBarbara RyanDirector · sold 500 at avg $10.855K2.2% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with INKT
Spot a number that looks wrong? Check it in INKT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing INKT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.